Mar 25
SLXNW · Silexion Therapeutics Corp · Documents
$0.00
+0.00 (+0.00%)
At close · Nov 19
Return incl. dividend (before tax)
Going-concern doubt
— flagged Nov 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As of September 30, 2026, we had cash and cash equivalents of $4.8 million. Based on our current cash balance, as well as our history of operating losses and negative cash flows from operations, combined with our anticipated use of cash to, among other things, (i) fund the clinical development of SIL204, (ii) identify and develop new product candidates, and (iii) seek approval for SIL204 and any other product candidates we may develop, our management has concluded that we do not have sufficient cash to fund our operations for 12 months from the issuance date of our consolidated financial statements for the three-month and nine-month periods ended September 30, 2026 included in this quarterly report, but rather, for only several months from the filing date of this quarterly report, under our current business plan, as a result, there is substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Nov 12, 2026
Market Cap
$974,292
Shares
649,528
Volume · Nov 19
300
Avg daily vol (3M)
39.06K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
2026
Mar 24
Mar 23
Mar 17
Annual report
10-K
FY2025, ended Dec 31
Annual report for FY2025
AI summary on its way
Net loss $11.91M
Diluted EPS $8.96
▼ 97.7%
Mar 16
Feb 23
Feb 13
Feb 3
Jan 6
2025
Dec 16
Current report
8-K
Regulation FD disclosure
Dec 2
Current report
8-K
Regulation FD disclosure
Nov 25
Current report
8-K
Regulation FD disclosure
Nov 12
Current report
8-K
Financial results
Nov 12
Quarterly report
10-Q
FY2025 Q3, ended Sep 30
Quarterly report for FY2025 Q3
Net loss $3.26M
Diluted EPS $2.88
▼ 98.9%
Oct 31
Registration statement
S-3
Registration statement
Sep 30
Current report
8-K
Regulation FD disclosure
Sep 26
Current report
8-K
Entered into a material agreement
Sep 26
Registration statement
S-3
Registration statement
Sep 25
Current report
8-K
Other events
Sep 15
Current report
8-K
Unregistered sale of equity, Other events
Sep 12
Current report
8-K
Events of Sep 11
Entered into a material agreement
Sep 12
Registration statement
424B4
Registration statement
Sep 11
Current report
8-K
Regulation FD disclosure
Sep 5
Registration statement
S-1
Registration statement
Sep 4
Current report
8-K
Regulation FD disclosure
Sep 2
Current report
8-K
Regulation FD disclosure
Aug 26
Registration statement
S-1
Registration statement
Aug 20
Current report
8-K
Other events
Aug 19
Current report
8-K
Charter or bylaw amendment, or fiscal year change, Shareholder vote results
Aug 12
Current report
8-K
Financial results
Aug 12
Quarterly report
10-Q
FY2025 Q2, ended Jun 30
Quarterly report for FY2025 Q2
Net loss $2.5M
Diluted EPS $4.32
▼ 97.8%
Aug 12
Proxy statement
DEFA14A
Proxy statement
Aug 1
Current report
8-K
Entered into a material agreement, Unregistered sale of equity
Jul 31
Proxy statement
DEF 14A
Proxy statement
Jul 31
Current report
8-K
Regulation FD disclosure
Jul 29
Jul 21
Current report
8-K
Delisting notice or listing transfer
Jul 21
Proxy statement
PRE 14A
Proxy statement
Jul 16
Current report
8-K
Other events
Jul 14
Current report
8-K
Shareholder vote results
Jul 9
Current report
8-K
Regulation FD disclosure
Jul 8
Current report
8-K/A
Other events
Jul 8
Current report
8-K
Other events
Jul 7
Proxy statement
DEFA14A
Proxy statement
Jun 23
Proxy statement
DEFA14A
Proxy statement
Jun 16
Proxy statement
DEF 14A
Proxy statement
Jun 5
Proxy statement
PRE 14A
Proxy statement
Jun 3
Current report
8-K
Other events
May 29
Current report
8-K
Regulation FD disclosure
May 23
Current report
8-K
Delisting notice or listing transfer
Showing 51–100 of 146 documents
Key facts
CIK
2022416
CUSIP
G1281K148
13F (30d)
27 filings
21 filers
Visit website
Investor relations